Page 48 - PACE: Advanced Prostate Cancer Consensus

Indirect Comparison of Abiraterone Acetate and

Docetaxel Using STAMPEDE Data: Efficacy

*
No Significant Difference in OS Failure-free Survival Analysis
Favoured Abiraterone

KM OS: abiraterone vs. docetaxel KM FFS: abiraterone vs docetaxel
1.0 1.0

0.8 0.8
Overall survival 0.6 Failure-free survival 0.6

0.4
0.4

0.2 0.2
SOC + DocP SOC + DocP
0.0 SOC + AAP 0.0 SOC + AAP

0 12 24 36 48 0 12 24 36 48
Number of patients Time from randomization (months) Number of patients Time from randomization (months)
(events) (events)
SOC + DocP 189 (1) 183 (7) 175 (5) 168 (7) 158 (7) 146 (4) 139 (10) 112 (2) 74 SOC + DocP 189 (11) 172 (20) 142 (20) 121 (11) 109 (8) 99 (5) 92 (5) 77 (5) 49

SOC + AAP 377 (3) 371 (8) 358 (10) 339 (17) 320 (12) 307 (24) 278 (9) 240 (12) 161 SOC + AAP 377 (16) 358 (37) 316 (25) 286 (11) 270 (11) 256 (7) 242 (5) 211 (7) 141

*Failure = radiologic, clinical or PSA progression or death from prostate cancer
AAP, abiraterone acetate with prednisolone; DocP, docetaxel with prednisolone; KM, Kaplan-Meier; SCC, squamous cell
carcinoma; SOC, standard of care
Adapted from Sydes MR, et al. Ann Oncol 2018;29:1235-1248.